Physician profile
Ivan Sabio
NPI 1629047709
$2,844.58
in general payments reported to CMS, 2019-2025
34 companies · $975 in 2025
The $975 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $97.00 · 2023: $833 · 2024: $940 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $551.05 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $275.66 | 2023-2025 | Mounjaro, Amyvid, Jardiance |
| Abbott Laboratories | $200.90 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $180.31 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $166.84 | 2023-2025 | |
| Novo Nordisk INC | $158.71 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Mylan Specialty L.P. | $129.94 | 2023-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $128.73 | 2024-2025 | Airsupra, Farxiga |
| Stryker Corporation | $97.00 | 2020 | |
| Amgen INC. | $87.46 | 2023-2025 | Repatha, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $82.45 | 2023-2025 | Rexulti |
| Sanofi Pasteur INC. | $81.69 | 2023-2025 | |
| Medtronic, INC. | $77.10 | 2025 | Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $64.07 | 2023-2024 | Eliquis |
| Xeris Pharmaceuticals, INC. | $60.07 | 2023-2025 | Gvoke Hypopen |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.21 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $46.31 | 2025 | Unithroid |
| Axsome Therapeutics, INC. | $45.90 | 2025 | Sunosi, Auvelity |
| Glaxosmithkline, LLC. | $35.84 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $29.99 | 2025 | Voquezna |
| Dexcom, INC. | $28.53 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.93 | 2025 | Caplyta |
| Corcept Therapeutics | $25.63 | 2024 | Korlym |
| Harmony Biosciences LLC | $25.56 | 2023 | Wakix |
| Paratek Pharmaceuticals, INC. | $24.53 | 2025 | Xhance, Nuzyra |
| Sumitomo Pharma America, INC. | $23.40 | 2024 | Gemtesa |
| Tandem Diabetes Care, INC. | $23.35 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eisai INC. | $23.26 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.61 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.40 | 2024 | Xifaxan |
| Recordati_rare_diseases_inc. | $15.93 | 2025 | Isturisa |
| Insulet Corporation | $15.42 | 2024 | Omnipod |
| Azurity Pharmaceuticals, INC. | $15.26 | 2023 | Horizant |
| Cequr Corporation | $11.54 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Sabio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.